FindTrial
Sign In

A dose finding study of KRN125

Phase 2 study of KRN125 (A dose finding study of KRN125 for chemotherapy-induced neutropenia in breast cancer)

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220922
Enrollment
Unknown
Registered
2009-11-20
Start date
2009-11-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced neutropenia

Interventions

investigational material(s) Generic name etc : KRN125 INN of investigational material : Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and Administration for I

Sponsors

Kyowa Hakko Kirin Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Written informed consent Diagnosed with stage II/III primary invasive breast cancer No prior chemotherapy Going to receive TAC treatment regimen as adjuvant or neoadjuvant chemotherapy ECOG PS =< 2 Appropriate bone marrow, hepatic, renal, and heart functions

Exclusion criteria

Exclusion criteria: Complication or anamnesis of cardiac disease, such as heart failure and severe arrhythmia Double cancer Primary hematologic disease such as myelodysplastic syndrome or aplastic anemia Undergoing interstitial pneumonia treatment Previous radiotherapy within 4 weeks of enrollment

Design outcomes

Primary

MeasureTime frame
Efficacy: duration of severe neutropenia—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026